Elevance Health stock holds near $397 as Q1 guidance lift shapes valuation
Published on 08/29/2026 at 09:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Elevance Health Inc. (US2855211023) stock was quoted at $396.92 on the New York Stock Exchange during the session on August 28, 2026, modestly below recent levels near $404 and reflecting a small intraday decline of 0.35% from a prior close at $399.11.
Q1 2026 earnings beat and guidance raise
Per a detailed research overview published on June 25, 2026, Elevance Health reported first quarter calendar 2026 revenue of $50.18 billion, up 2.9% year on year and ahead of analyst estimates of $48.33 billion.
The same Q1 2026 report highlighted adjusted earnings per share of $12.58 versus consensus estimates of $10.81, marking a 16.4% beat that underlines management's ability to convert premium growth and cost controls into profit.
In that Q1 2026 update, Elevance Health also raised its full-year adjusted EPS guidance to $26.75 at the midpoint, representing a 4.9% increase over the prior outlook and signaling confidence in the earnings trajectory for the rest of calendar 2026.
The quarter's profitability metrics stood out as well, with an adjusted operating margin of 16.4% compared with 6.4% in the same quarter a year earlier, an improvement of 10.0 percentage points that points to both underwriting discipline and efficiency gains across the health benefits and services portfolio.
Free cash flow generation improved materially in Q1 2026, with a margin of 8.2% versus 1.7% a year earlier, creating more flexibility for share repurchases, debt reduction, and continued investment in technology and care management capabilities.
Valuation versus price targets and recent trading
The Q1 2026 research overview noted that Elevance Health's stock price of $383.14 at that time implied a forward price-to-earnings ratio of 15, set against Wall Street's consensus one-year price target of $415.81, which suggested 8.5% upside based on the then-current share price.
More recent sector commentary dated August 28, 2026 pointed out that Elevance Health shares were trading at $404.91 following the second quarter 2026 results review, with the stock down 5.1% since that Q2 report even though quarterly revenue of $49.83 billion was described as flat year on year and slightly ahead of analysts' expectations by 2.5%.
For investors comparing those levels to intraday quotes on August 28, 2026, the $396.92 price reported during that session left the stock several dollars below the $404.91 snapshot mentioned in the sector recap, illustrating how short-term volatility can open or close valuation gaps even when underlying fundamentals appear steady.
A separate valuation-focused analysis on August 28, 2026 framed the narrative around a last close of $399.11 and indicated that a commonly cited fair value estimate of $449.10 implied a material gap between modeled intrinsic value and the prevailing share price, based on assumptions about revenue growth, margins, and discount rates.
That same discussion highlighted how efficiency gains driven by artificial intelligence tools and leadership changes at Elevance Health's services arm Carelon are used by some market observers to support the case for higher medium-term earnings power relative to the current share price in the high $390s.
Momentum after Q2 2026 in the health insurance segment
The second quarter 2026 recap for health insurance providers emphasized that Elevance Health produced Q2 2026 revenue of $49.83 billion, which was characterized as flat compared with the prior-year period but nonetheless exceeded consensus expectations by 2.5%, reinforcing the picture of stable top-line performance in a competitive environment.
Despite that Q2 2026 beat, the sector review noted that Elevance Health's stock had declined 5.1% since reporting, trading at $404.91 at the time of that commentary, suggesting that investors were weighing the strong earnings profile against macro factors such as medical cost trends, regulatory noise, and broader rotation within the healthcare sector.
Coming back to August 28, 2026 intraday data, the share price movement from a previous close at $401.17 down to $396.92 during the day encapsulated a modest -0.35% change within the session, a move that keeps Elevance Health stock in a relatively tight band below $400 even as valuation narratives point to upside potential versus modeled fair value levels.
For context, the Q1 2026 research snapshot had recorded the stock as remaining flat at $329.70 immediately after those first-quarter results, implying that subsequent months brought a substantial price appreciation from the low $330s to recent trading near $400, supported by the earnings beats and the higher full-year guidance.
When viewed alongside the consensus one-year price target of $415.81 and a fair value estimate of $449.10 cited in valuation commentary, the current price range between $396.92 and $404.91 presents a picture of Elevance Health shares trading below some modeled intrinsic value scenarios but within reach of analyst targets if earnings delivery continues.
Carelon services and AI-driven efficiency
The valuation-focused article published on August 28, 2026 referenced efficiency gains supported by AI-driven tools within Elevance Health's operations and noted leadership changes at Carelon, the company's services division that encompasses care management, analytics, and technology-enabled support for health plans and providers.
Carelon sits at the center of Elevance Health's strategy to integrate data, care coordination, and digital platforms across its health benefits offerings, aiming to reduce avoidable medical costs and improve outcomes by intervening earlier in patient journeys and targeting high-risk populations more effectively.
By pairing advanced analytics with clinical insights, Carelon is designed to help Elevance Health manage medical trend volatility and deploy targeted programs that can stabilize loss ratios, which in turn support the margin expansion evidenced by the Q1 2026 operating margin move from 6.4% to 16.4%.
Leadership changes mentioned in recent commentary reflect the company's effort to keep Carelon aligned with evolving technology trends and regulatory expectations, with new executives expected to focus on scaling AI applications while ensuring robust data governance and compliance across diverse state and federal programs.
For investors, the Carelon story matters because sustained efficiency gains and differentiated service capabilities can underpin the higher EPS guidance announced for full-year 2026 and provide a buffer if macro or policy headwinds pressure premium growth or medical utilization patterns.
Core Elevance Health products and member experience
At the heart of Elevance Health's business are its commercial and government health plans, which offer medical coverage, pharmacy benefits, and supplemental services across employer groups, individual markets, Medicare, and Medicaid populations.
These health plans are increasingly supported by digital tools and personalized outreach, aiming to improve member engagement and adherence to preventive care schedules, medication regimens, and chronic disease management programs.
Elevance Health also deploys telehealth and virtual care services within its product set, giving members more flexibility to access in-network providers and behavioral health support without the need for in-person visits, which can help reduce barriers to care and improve satisfaction scores.
Carelon's analytics and coordination capabilities feed into these products by identifying gaps in care and high-risk cohorts, enabling targeted programs such as nurse-led outreach, social determinants of health interventions, and integrated pharmacy management solutions.
Over time, the combination of traditional health benefits products with data-driven services is intended to differentiate Elevance Health in a crowded health insurance marketplace and support both growth and margin resilience.
Shares anchored below $400 with upside narratives
As of August 28, 2026, Elevance Health stock's intraday quote at $396.92 on the New York Stock Exchange offers a concrete snapshot of where the shares currently trade within a band that has recently included levels such as $399.11 at the last close and $404.91 in sector reviews.
With Q1 2026 revenue of $50.18 billion, adjusted EPS of $12.58, and full-year adjusted EPS guidance raised to $26.75, Elevance Health presents an earnings profile that recent research has described as supportive of valuation metrics around 15 times forward earnings and price targets in the low $400s.
The quantified comparison between the current trading range just under $400 and consensus expectations at $415.81, as well as fair value modeling near $449.10, highlights a gap that some investors interpret as potential upside if the company continues to deliver on its margin, cash flow, and efficiency initiatives.
At the same time, the fact that the stock is down 5.1% since the Q2 2026 report despite a 2.5% revenue beat and stable year-on-year sales underscores that macro, regulatory, and sector-rotation factors can weigh on health insurer valuations even when company-specific metrics look solid.
For market participants tracking Elevance Health stock into the coming months, the key variables will likely include how medical cost trends evolve, whether Carelon's AI-driven efficiency programs sustain margin improvements, and how closely actual EPS delivery tracks the raised full-year 2026 guidance.
Read more
Further analysis of Elevance Health's Q1 2026 earnings and guidance
Product spotlight: Elevance Health commercial plans
One representative Elevance Health product is its suite of commercial employer health plans, which provide medical coverage, pharmacy benefits, and integrated wellness programs to large and mid-sized companies across the United States.
These plans typically combine broad provider networks with digital tools for benefits navigation, cost transparency, and telehealth access, helping employees understand coverage details and connect to appropriate care settings more quickly.
Employers often select Elevance Health commercial plans for their ability to pair claims administration with analytics-driven population health strategies, leveraging Carelon's capabilities to identify high-risk groups and deploy interventions that may reduce future medical expenditures.
From an employee perspective, features such as mobile apps, virtual primary care options, and personalized wellness incentives are intended to make the health plan experience more intuitive and supportive, aligning clinical outcomes with workforce productivity goals.
Stock snapshot and investor view
Based on intraday market data as of August 28, 2026, 2:02 p.m. ET, Elevance Health stock traded at $396.92 on the New York Stock Exchange, situating the shares slightly below the last close near $399 and under the $404.91 level cited in recent sector coverage, while consensus price targets and valuation models continue to point toward higher levels if earnings delivery remains on track.
Fact box
Company: Elevance Health Inc.
ISIN: US2855211023
Ticker: ELV
Exchange: New York Stock Exchange
Price (as of August 28, 2026, 2:02 p.m. ET): $396.92 USD
Market cap: $49.83 billion (as of August 28, 2026)
Sector / Industry: Health Care / Managed Health Care
Index membership: S&P 500
